Published in Proc Natl Acad Sci U S A on July 18, 2000
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets (2009) 1.52
Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling. J Biol Chem (2008) 1.40
Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem (2010) 1.36
Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J (2010) 1.25
Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther (2008) 1.23
Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol Cell Biol (2003) 1.19
Intravesical treatments of bladder cancer: review. Pharm Res (2008) 1.16
Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol (2010) 1.08
Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol (2011) 1.03
Positional information is reprogrammed in blastema cells of the regenerating limb of the axolotl (Ambystoma mexicanum). PLoS One (2013) 0.99
Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res (2013) 0.98
A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer (2006) 0.95
A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells. Breast Cancer Res Treat (2014) 0.91
Acidic and basic fibroblast growth factors involved in cardiac angiogenesis following infarction. Int J Cardiol (2010) 0.91
A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells. PLoS One (2011) 0.88
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol (2012) 0.85
Generation of Multicellular Tumor Spheroids with Microwell-Based Agarose Scaffolds for Drug Testing. PLoS One (2015) 0.84
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer (2014) 0.83
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol (2010) 0.83
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Ann Oncol (2008) 0.83
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer (2008) 0.83
Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance. J Transl Med (2008) 0.80
Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells. Clin Exp Metastasis (2014) 0.80
Dysregulation of janus kinases and signal transducers and activators of transcription in cancer. Am J Cancer Res (2011) 0.80
Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression. Cancer Cell Int (2015) 0.78
Fibroblast growth factors, old kids on the new block. Semin Cell Dev Biol (2016) 0.78
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor. Cancer Chemother Pharmacol (2015) 0.77
Basic fibroblast growth factor impact on retinoblastoma progression and survival. Invest Ophthalmol Vis Sci (2008) 0.76
Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs. AAPS J (2010) 0.75
Small role with big impact: miRNAs as communicators in the cross-talk between cancer-associated fibroblasts and cancer cells. Int J Biol Sci (2017) 0.75
Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin. AAPS J (2014) 0.75
PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. Acta Pharm Sin B (2014) 0.75
Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells. Oncol Lett (2010) 0.75
Differential effects of amnion and chorion membrane extracts on osteoblast-like cells due to the different growth factor composition of the extracts. PLoS One (2017) 0.75
Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women. Oncol Lett (2017) 0.75
New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46
Human endothelial cell growth factor: cloning, nucleotide sequence, and chromosome localization. Science (1986) 4.17
Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst (1994) 2.50
Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res (1998) 1.52
Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol (1999) 1.35
Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer (1996) 1.33
Human brain fibroblast growth factor. Isolation and partial chemical characterization. FEBS Lett (1985) 1.27
Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res (1998) 1.15
Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia (1997) 1.14
Nature of the interaction of growth factors with suramin. Biochemistry (1992) 1.07
Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer (1993) 1.05
Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene (1997) 1.03
A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem Biophys Res Commun (1991) 0.99
The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor. Invest Urol (1981) 0.98
Purification and some properties of a lung-derived growth factor that differentially stimulates the growth of tumor cells metastatic to the lung. Cancer Res (1989) 0.93
How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Eur J Cancer (1996) 0.90
Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion. Gen Pharmacol (1997) 0.90
Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells. J Cell Physiol (1998) 0.89
Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells. Cancer Res (1997) 0.87
Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification. Oncogene (1994) 0.86
Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett (1998) 0.85
Aberrant expression of basic fibroblast growth factor in NIH-3T3 cells alters drug resistance and gene amplification potential. Exp Cell Res (1994) 0.82
Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. J Surg Oncol (1998) 0.82
Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics. Pharm Res (1996) 0.81
Epidermal growth factor and insulin-like growth factor-1 protect MDA-231 cells from death induced by actinomycin D: the involvement of growth factors in drug resistance. In Vitro Cell Dev Biol Anim (1994) 0.80
Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application. Clin Chim Acta (1999) 0.79
Factors influencing phenotypic diversity of human prostate carcinoma cells metastasizing in athymic nude mice. Exp Cell Biol (1985) 0.79
Effect of suramin on human esophageal cancer cells in vitro and in vivo. Scand J Gastroenterol (1997) 0.78
Establishment of monoclonal antibodies against human acidic fibroblast growth factor. Biochem Biophys Res Commun (1991) 0.78
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood (1998) 6.26
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst (2001) 2.82
Experimental observations of stress-driven grain boundary migration. Science (2009) 2.18
Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem (2000) 1.72
Long-term follow-up on an intensified treatment regimen for advanced resectable head and neck squamous cell carcinomas. Cancer Invest (2001) 1.40
Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther (1999) 1.32
Determinants of drug delivery and transport to solid tumors. J Control Release (2001) 1.24
Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther (2001) 1.20
Computational model of intracellular pharmacokinetics of paclitaxel. J Pharmacol Exp Ther (2000) 1.16
Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res (1998) 1.15
Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res (1982) 1.14
Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci (2001) 1.06
Nitrate and glutamate sensing by plant roots. Biochem Soc Trans (2005) 1.01
The viral oncogene Np9 acts as a critical molecular switch for co-activating β-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells. Leukemia (2013) 0.97
Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther (2001) 0.97
Engraftment and development of human T and B cells in mice after bone marrow transplantation. Science (1991) 0.96
Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther (2001) 0.94
Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res (2001) 0.94
Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs (2001) 0.94
Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. Clin Cancer Res (2001) 0.92
Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol (1999) 0.92
Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res (1991) 0.90
Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res (1991) 0.90
Expression of vigilin in chicken cartilage and bone. Cell Tissue Res (1993) 0.89
Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res (1998) 0.89
Hyperbaric oxygen reduces inflammatory response in acute pancreatitis by inhibiting NF-kappaB activation. Eur Surg Res (2009) 0.89
Kinetics of hallmark biochemical changes in paclitaxel-induced apoptosis. AAPS PharmSci (1999) 0.88
Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol (1997) 0.88
Apoptosis: a new pharmacodynamic endpoint. Pharm Res (1997) 0.88
Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats. Antimicrob Agents Chemother (1992) 0.88
A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall. Pharm Res (1991) 0.88
T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther (2002) 0.87
BLyS BINDS TO B CELLS WITH HIGH AFFINITY AND INDUCES ACTIVATION OF THE TRANSCRIPTION FACTORS NF-kappaB AND ELF-1. Cytokine (2001) 0.87
Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep (1979) 0.86
Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells. Antimicrob Agents Chemother (1994) 0.86
Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res (1998) 0.86
Cytostatic and apoptotic effects of paclitaxel in human breast tumors. Cancer Chemother Pharmacol (1998) 0.86
Evidence for multiple binding sites for several components of human lymphoblastoid interferon-alpha. J Biol Chem (1993) 0.86
Extraction of intracellular nucleosides and nucleotides with acetonitrile. Clin Chem (1989) 0.86
Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors. Pharm Res (1998) 0.86
Pharmacodynamics of doxorubicin in human prostate tumors. Clin Cancer Res (1998) 0.85
Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res (1991) 0.85
2',3'-Dideoxyinosine is not metabolized in human placenta. Drug Metab Dispos (1993) 0.85
Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures. Pharm Res (1998) 0.84
Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol (1993) 0.84
Penetration of mitomycin C in human bladder. Cancer Res (1993) 0.84
Pharmacodynamics of taxol in human head and neck tumors. Cancer Res (1996) 0.84
Genetic etiology and dental pulp cell deficiency of hypophosphatasia. J Dent Res (2010) 0.84
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Ann Oncol (2008) 0.83
Isocratic high-performance liquid chromatographic assay of taxol in biological fluids and tissues using automated column switching. J Chromatogr B Biomed Appl (1995) 0.83
Gastrointestinal and hepatic first-pass elimination of 2',3'-dideoxyinosine in rats. J Pharmacol Exp Ther (1993) 0.83
The role of Leptotrombidium scutellare in the transmission of human diseases. Chin Med J (Engl) (1996) 0.82
The role of the Sphingomonas species UG30 pentachlorophenol-4-monooxygenase in p-nitrophenol degradation. FEMS Microbiol Lett (1999) 0.82
A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Cancer Chemother Pharmacol (2000) 0.82
Telomere amount and length assay. Pharm Res (2001) 0.82
Design and analysis of in vitro antitumor pharmacodynamic studies. Cancer Res (1995) 0.81
[Nationwide survey of the distribution of parasites in China--the characteristics and rules of geographic distribution of human helminth infection]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (1995) 0.81
Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures. Pharm Res (1996) 0.81
Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum. Pharm Res (1993) 0.81
Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics. Pharm Res (1996) 0.81
Effect of beta-sitosterol, a plant sterol, on growth, protein phosphatase 2A, and phospholipase D in LNCaP cells. Nutr Cancer (2000) 0.81
Penetration of intravesical doxorubicin in human bladders. Cancer Chemother Pharmacol (1996) 0.80
Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. Clin Cancer Res (1997) 0.80
Hydroxylated metabolies of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) in rats and rabbits. Cancer Res (1978) 0.80
Effect of interstitial cystitis on drug absorption from urinary bladder. J Pharmacol Exp Ther (1994) 0.80
Regional heterogeneity and pharmacodynamics in human solid tumor histoculture. Cancer Chemother Pharmacol (1999) 0.80
Pharmacokinetics of oral 2',3'-dideoxyinosine in rats. Pharm Res (1992) 0.80
Binding of taxol to plastic and glass containers and protein under in vitro conditions. J Pharm Sci (1996) 0.80
Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J Urol (1994) 0.80